Passive Immunotherapy for Ebola Virus Infection

Ebola virus infection

Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates.

The survival of 7 of 8 patients with Ebola virus (EBOV) infection after transfusions of convalescent-phase blood during a 1995 outbreak of EBOV infection is frequently cited as evidence that passive immunotherapy is a viable treatment option. To test whether whole-blood transfusions were more efficacious than passively administered immunoglobulins or monoclonal antibodies, we transfused convale...

Ebola virus-like particles protect from lethal Ebola virus infection.

The filovirus Ebola causes hemorrhagic fever with 70-80% human mortality. High case-fatality rates, as well as known aerosol infectivity, make Ebola virus a potential global health threat and possible biological warfare agent. Development of an effective vaccine for use in natural outbreaks, response to biological attack, and protection of laboratory workers is a higher national priority than e...

Ebola Infection and Diabetes Mellitus

Diabetes mellitus is the common endocrine problem that affects millions of world population. The disease can be seen in every country around the world. It is recorded as one of the most common noninfectious disease at present. In the era of the new emerging diseases, the concern on the effect of new diseases on diabetes should be discussed. For example, in the case of new emerging zoonotic infl...

Ebola virus infection modeling and identifiability problems

The recent outbreaks of Ebola virus (EBOV) infections have underlined the impact of the virus as a major threat for human health. Due to the high biosafety classification of EBOV (level 4), basic research is very limited. Therefore, the development of new avenues of thinking to advance quantitative comprehension of the virus and its interaction with the host cells is urgently needed to tackle t...